Genomics Sector Holds Firm as Rocket Pharma Soars and Fulgent Genetics Plummets

The genomics sector demonstrated notable resilience on March 1, 2026, with the benchmark Genomics ETF (GNOM) posting only a minor decline of 0.19%. This performance stood in contrast to the broader market, as the S&P 500 fell 0.48% during the same session. Market breadth within the sector was nearly balanced, with 22 stocks advancing against 24 decliners, suggesting that price action was driven by company-specific events rather than a widespread sell-off.

The day's trading was defined by starkly divergent fortunes. Rocket Pharmaceuticals (RCKT) led the sector with a double-digit gain fueled by positive regulatory sentiment, while Fulgent Genetics (FLGT) cratered after issuing a disappointing revenue forecast.

Rocket Pharmaceuticals Inc. (RCKT) surged 10.6% to close at $5.01, propelled by investor optimism ahead of several key FDA decisions anticipated for the biotech sector in March. The move was further supported by a Morgan Stanley report identifying RCKT as a prime beneficiary of a potential biotech recovery in 2026. A mildly bullish signal score of 15 and a bullish RSI divergence underpinned the positive sentiment, suggesting growing momentum.

Other notable gainers included Illumina Inc. (ILMN), which climbed 5.54% to $134.46 after its whole-genome sequencing technology was chosen to accelerate rare disease testing in Florida. Despite the gain and a neutral signal score of 0, a bearish RSI divergence indicates that some underlying technical pressure may persist. Prime Medicine Inc. (PRME) rose 5.48% to $4.62 following news of a management change, while 10x Genomics Inc. (TXG) advanced 4.16% to $23.05 and Moderna Inc. (MRNA) gained 3.6% to $53.57, with both moves appearing to be technically driven in the absence of fresh catalysts.

On the downside, Fulgent Genetics Inc. (FLGT) was the session's biggest loser, plummeting 38.09% to $15.33. The catastrophic drop followed the company's 2026 revenue forecast of $350 million, which the market received poorly despite projections of 53% average selling price growth. A strongly bearish signal score of -20, compounded by a bearish MACD divergence, highlighted the intense selling pressure.

Uniqure NV (QURE) also faced a difficult session, falling 8.68% to $15.63. The decline came as Wolfe Research initiated coverage with a lukewarm "Peer Perform" rating and a deadline in a securities class action lawsuit approached. A bearish signal score of -17 and a strong bearish MACD divergence pointed to sustained negative momentum for the stock.

In a more complex technical picture, Wave Life Sciences Ltd. (WVE) dropped 9.31% to $13.93 around its earnings announcement. However, the stock holds a bullish signal score of 7 and exhibits a bullish MACD divergence, suggesting the sell-off might be an overreaction or technically driven, rather than a reflection of deteriorating fundamentals. Meanwhile, Pacific Biosciences (PACB) fell 5.62% to $1.68 and Veracyte Inc. (VCYT) declined 5.49% to $36.59, with both moves appearing technical in nature.

For traders, several key levels have emerged for the sector's most active stocks. Rocket Pharmaceuticals now faces resistance at $4.6617; a break above this level could signal continued upside, whereas a drop below its pivot at $4.4183 would challenge the current rally.

Following its dramatic sell-off, Fulgent Genetics finds critical support at $23.9117. A failure to hold this line could trigger further declines, while any recovery attempt must first overcome its pivot point at $24.4083.

The technical divergence in Wave Life Sciences makes it a compelling name to watch. Its ability to hold support at $14.57 and reclaim its pivot at $15.02 will be crucial in determining if the bullish underlying signals can overcome the recent price weakness.

Looking at five-day momentum, volatility remains high. Prime Medicine (+38.32%) and Rocket Pharmaceuticals (+25.56%) have been the strongest performers over the past week. In contrast, Uniqure (-36.13%) and Fulgent Genetics (-33.38%) have faced significant selling pressure, underscoring the catalyst-driven environment across the genomics landscape.

This content is provided for educational and informational purposes only. It is not intended as, and should not be relied upon for, financial, investment, or other advice. Investing in financial markets involves risks, including the loss of principal. Past performance does not guarantee future results. Always consult with a qualified financial professional before making any investment decisions. Individual results may vary, and the information presented here does not account for individual financial situations or risk tolerances.